Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

Not Applicable

Not yet recruiting

• Conditions: Parkinson's Disease

• Registration Number: NCT07216976
• Lead Sponsor: MedtronicNeuro

Brief Summary

The purpose of the study is to evaluate the effectiveness of the Medtronic Percept PC with Adaptive DBS therapy (aDBS) for Parkinson's Disease in China.

The main question it aims to answer is: To demonstrate at least 50% of subjects meet a success criterion relative to stable cDBS.

Detailed Description

The ADAPT-PD China Study will utilize both Dual and Single Threshold aDBS modes (algorithms). Prospective, multicenter, open label comparison (with single-blind aDBS mode from aDBS randomization to evaluation phase), single arm clinical trial designed to evaluate the effectiveness of the Medtronic Percept PC INS with aDBS for Parkinson's Disease in China.

The study is expected to be conducted at approximately 5 centers located in China.

Study Timeline

• Status Verified: 2025-10
• Study First Submitted: 2025-10-09
• Study First Submitted QC: 2025-10-14
• Last Update Submitted: 2025-10-14
• Study First Posted: 2025-10-15
• Last Update Posted: 2025-10-15
• Study Start: 2025-11-01
• Primary Completion: 2027-01
• Study Completion: 2028-01-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

1. Subjects must meet all general inclusion/exclusion criteria (as assessed at the Enrollment Visit)
2. Subjects must meet the LFP screening inclusion criterion (as assessed at the LFP Screening Visit)

General (Assessed at Enrollment Visit):

1. Subject has idiopathic Parkinson's disease
2. Subject is implanted (>3 months prior to enrollment for new INS implants or >1 month from INS replacement) with Percept PC (Model B35200) and Medtronic DBS leads (Model 3387, 3389, B33005 or B33015) and extensions (Model 37086 or B34000) bilaterally in the same target (physician confirmed), STN or GPi
3. In the opinion of the investigator, the subject responds to DBS Therapy.
4. Based on the opinion of the investigator, the subject's cDBS parameters and PD medications are stable (no changes within the last 4 weeks) and expected to remain stable from enrollment through the end of the aDBS Evaluation Phase
5. Subject is configured to monopolar or dual monopolar stimulation using contacts 1 and/or 2 (9 and/or 10) on at least one side
6. Subject is willing and able to attend all study-required visits and complete the study procedures (e.g. 1-month recall questionnaires, MDS-UPDRS III, Off stim/Off med visit)
7. Subject (or legally authorized representative) has the ability to understand and provide written informed consent for participation in the study prior to the study-related procedures being conducted
8. Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active, must be using, or agree to use, a medically-acceptable method of birth control as confirmed by the investigator

LFP Screening Inclusion Criteria (Conducted during LFP Screening Visit):

1. Subject has Alpha - Beta band (8-30 Hz) amplitude ≥ 1.2 μVp detected on either left and/or right DBS leads on sensing channels 0-2, 0-3, 1-3, 8-10, 8-11, or 9-11.

Exclusion Criteria

General (Assessed at the Enrollment Visit):

1. Subject and/or caregiver is unable to utilize the patient programmer
2. Subject has more than one lead in each hemisphere of the brain
3. Subject has cortical leads or additional unapproved hardware implanted in the brain
4. Subject has more than one INS
5. At enrollment, the subject's INS has a predicted battery life of <1 year
6. Subject has Beck Depression Inventory II (BDI-II)>25
7. Subject requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT)
8. Subject has a metallic implant in the head, (e.g., aneurysm clip, cochlear implant)
9. Subject has, or plans to obtain, an implanted electrical stimulation medical device anywhere in the body (e.g., cardiac pacemaker, defibrillator, spinal cord stimulator)
10. Subject has, or plans to obtain, an implanted medication pump for the treatment of Parkinson's disease (e.g., DUOPATM infusion pump) and/or portable infusion pump
11. Based on the opinion of the investigator, the subject has an abnormal neurological examination that would preclude them from study participation
12. Subject is breast feeding
13. Subject is under the age of 18 years
14. Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound the results of this study as determined by the Medtronic study team
15. Subjects with signal artifact on all 6 aDBS sense pathways (3 each on both DBS leads) which preclude the clinician from setting thresholds

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
"On" time without troublesome dyskinesia (i.e. Good "On" Time)	From the cDBS baseline to aDBS evaulation phase at about 1 month	Proportion of aDBS subjects meet a success criterion relative to stable cDBS.The success criterion: no worse than 2 hours/day less of "On" time without troublesome dyskinesia (i.e. Good "On" Time) during aDBS compared to cDBS.

Trial Locations

Locations (5)

Xuanwu Hospital; 🇨🇳 Beijing, Beijing Municipality, China

Sun Yat-sen Hospital; 🇨🇳 Guangzhou, Guangdong, China

Huashan Hospital; 🇨🇳 Shanghai, Shanghai Municipality, China

Ruijin Hospital; 🇨🇳 Shanghai, Shanghai Municipality, China

West China Hospital; 🇨🇳 Chengdu, Sichuan, China